Precipitation of acute angle closure glaucoma following withdrawal of donepezil hydrochloride

Thresika, Uvaraj; Nayana, Sebastian

doi:10.18203/2349-3933.ijam20150570

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, angle-closure glaucoma has been reported after abrupt discontinuation of oral donepezil. 35,36 Per Enzenauer and Bowers, a 55-year-old newly diagnosed patient with AD was on 10 mg daily donepezil hydrochloride and no other pharmacotherapy for 4 to 6 months. 3 5 Within 3 to 5 days of running out of the donepezil, the patient presented to the emergency department with 12 hours’ severe right-sided headache, photophobia, reduced vision, nausea, and vomiting.…”

Section: Vision Problemsmentioning

confidence: 99%

Acetylcholinesterase Inhibitors: Beneficial Effects on Comorbidities in Patients With Alzheimer’s Disease

Kaushik¹,

Smith

Mikobi

et al. 2017

Am J Alzheimers Dis Other Demen

View full text Add to dashboard Cite

Elderly patients with Alzheimer's disease (AD) and other dementias are at high risk of polypharmacy and excessive polypharmacy for common coexisting medical conditions. Polypharmacy increases the risk of drug-drug and drug-disease interactions in these patients who may not be able to communicate early symptoms of adverse drug events. Three acetylcholinesterase inhibitors (ACHEIs) have been approved for AD: donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne). They are also used off-label for other causes of dementia such as Lewy body and vascular dementia. We here report evidence from the literature that ACHEI treatment, prescribed for cognitive impairment, can reduce the load of medications in patients with AD by also addressing cardiovascular, gastrointestinal, and other comorbidities. Using one drug to address multiple symptoms can reduce costs and improve medication compliance.

show abstract

Section: Vision Problemsmentioning

confidence: 99%